Inhaled Carbon Monoxide
Phase 2Small molecule
Inhaled Carbon Monoxide is one of 96 small molecule programs targeting Paralysis. It is currently in Phase 2.
3
Indications
3
Total Trials
0
Active Trials
95
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
476 competitors in Kidney Transplant
#DrugCompanyPhaseTrials
1Nulojix
Bristol-Myers SquibbPreclinical
Simulect
NovartisPreclinical
Medrol
PfizerPreclinical
Zinbryta
RochePreclinical
Zemplar
AbbViePreclinical
Cysteine Hydrochloride
NovartisPreclinical
Sensipar
AmgenPreclinical
Epogen
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.Preclinical
Radicava
ShionogiPreclinical
Inhaled Carbon Monoxide
MMallinckrodt
Phase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Paralysis1 trial
Idiopathic Pulmonary Fibrosis1 trial
Study of Inhaled Carbon Monoxide to Treat Idiopathic Pulmonary Fibrosis
Completed·—·Phase 2·NCT01214187·58 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Inhaled Carbon Monoxide. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- MMallinckrodt